IDO1 and Merkel cell skin cancer: Moreover, Harms et al. (2021) recently found that MCPyV-positive MCC patients also showing decreased tumoral expression of granzyme B and IDO-1 have shorter survival when compared to MCPyV-negative MCC patients.